Cytokines as adjuvants for vaccine and cellular therapies for cancer

Christian M. Capitini, Terry J. Fry, Crystal L. Mackall

Research output: Contribution to journalArticle

Abstract

Problem statement: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. Approach: The gamma (γ) family of cytokines offered a unique opportunity to support the expansion and effectors potential of vaccine-responding T-cells, as well as stimulate other effectors, such as Natural Killer (NK) cells, to become activated. Results: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as had been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offered the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrated that IL-15 could also improve T-cell and especially NK-cell, responses as well. Conclusion/Recommendations: Future study should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.

Original languageEnglish (US)
Pages (from-to)65-83
Number of pages19
JournalAmerican Journal of Immunology
Volume5
Issue number3
StatePublished - 2009
Externally publishedYes

Fingerprint

Active Immunotherapy
Vaccines
Cytokines
Interleukin-15
Interleukin-7
Neoplasms
Regulatory T-Lymphocytes
Natural Killer Cells
T-Lymphocytes
Residual Neoplasm
Immunosuppression
Interleukin-2
Recurrence
Therapeutics

Keywords

  • Interleukin 15
  • Interleukin 2
  • Interleukin 21
  • Interleukin 7
  • Tumor vaccines

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Capitini, C. M., Fry, T. J., & Mackall, C. L. (2009). Cytokines as adjuvants for vaccine and cellular therapies for cancer. American Journal of Immunology, 5(3), 65-83.

Cytokines as adjuvants for vaccine and cellular therapies for cancer. / Capitini, Christian M.; Fry, Terry J.; Mackall, Crystal L.

In: American Journal of Immunology, Vol. 5, No. 3, 2009, p. 65-83.

Research output: Contribution to journalArticle

Capitini, CM, Fry, TJ & Mackall, CL 2009, 'Cytokines as adjuvants for vaccine and cellular therapies for cancer', American Journal of Immunology, vol. 5, no. 3, pp. 65-83.
Capitini, Christian M. ; Fry, Terry J. ; Mackall, Crystal L. / Cytokines as adjuvants for vaccine and cellular therapies for cancer. In: American Journal of Immunology. 2009 ; Vol. 5, No. 3. pp. 65-83.
@article{3c02eb8707684490963e64dbb201a59f,
title = "Cytokines as adjuvants for vaccine and cellular therapies for cancer",
abstract = "Problem statement: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. Approach: The gamma (γ) family of cytokines offered a unique opportunity to support the expansion and effectors potential of vaccine-responding T-cells, as well as stimulate other effectors, such as Natural Killer (NK) cells, to become activated. Results: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as had been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offered the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrated that IL-15 could also improve T-cell and especially NK-cell, responses as well. Conclusion/Recommendations: Future study should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.",
keywords = "Interleukin 15, Interleukin 2, Interleukin 21, Interleukin 7, Tumor vaccines",
author = "Capitini, {Christian M.} and Fry, {Terry J.} and Mackall, {Crystal L.}",
year = "2009",
language = "English (US)",
volume = "5",
pages = "65--83",
journal = "American Journal of Immunology",
issn = "1553-619X",
publisher = "Science Publications",
number = "3",

}

TY - JOUR

T1 - Cytokines as adjuvants for vaccine and cellular therapies for cancer

AU - Capitini, Christian M.

AU - Fry, Terry J.

AU - Mackall, Crystal L.

PY - 2009

Y1 - 2009

N2 - Problem statement: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. Approach: The gamma (γ) family of cytokines offered a unique opportunity to support the expansion and effectors potential of vaccine-responding T-cells, as well as stimulate other effectors, such as Natural Killer (NK) cells, to become activated. Results: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as had been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offered the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrated that IL-15 could also improve T-cell and especially NK-cell, responses as well. Conclusion/Recommendations: Future study should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.

AB - Problem statement: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. Approach: The gamma (γ) family of cytokines offered a unique opportunity to support the expansion and effectors potential of vaccine-responding T-cells, as well as stimulate other effectors, such as Natural Killer (NK) cells, to become activated. Results: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as had been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offered the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrated that IL-15 could also improve T-cell and especially NK-cell, responses as well. Conclusion/Recommendations: Future study should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.

KW - Interleukin 15

KW - Interleukin 2

KW - Interleukin 21

KW - Interleukin 7

KW - Tumor vaccines

UR - http://www.scopus.com/inward/record.url?scp=70349560862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349560862&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70349560862

VL - 5

SP - 65

EP - 83

JO - American Journal of Immunology

JF - American Journal of Immunology

SN - 1553-619X

IS - 3

ER -